- Report
- October 2024
- 181 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- March 2025
- 192 Pages
Global
From €4699EUR$4,950USD£3,964GBP
- Report
- February 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- May 2024
- 133 Pages
Global
From €6170EUR$6,499USD£5,204GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1899EUR$2,000USD£1,602GBP
- Report
- June 2024
- 200 Pages
Global
From €7547EUR$7,950USD£6,366GBP
- Clinical Trials
- April 2024
- 180 Pages
Global
From €2373EUR$2,500USD£2,002GBP
- Report
- July 2024
- 188 Pages
Global
From €4272EUR$4,500USD£3,603GBP
- Report
- January 2022
- 60 Pages
Global
From €3750EUR$3,950USD£3,163GBP
- Report
- October 2023
- 90 Pages
United States
From €3323EUR$3,500USD£2,803GBP
- Report
- March 2024
- 200 Pages
Global
From €3940EUR$4,150USD£3,323GBP
- Report
- April 2023
- 112 Pages
Global
From €4509EUR$4,750USD£3,804GBP
From €14235EUR$14,995USD£12,008GBP
- Report
- May 2021
- 42 Pages
Global
From €3793EUR$3,995USD£3,199GBP
- Report
- August 2023
- 125 Pages
Global
From €3500EUR$3,949USD£3,056GBP
- Report
- October 2022
- 532 Pages
Global
From €2373EUR$2,500USD£2,002GBP
The Endometrial Cancer Drug market is a subset of the Uterine Cancer Drugs market, which is composed of drugs used to treat endometrial cancer, a type of cancer that affects the lining of the uterus. Endometrial cancer drugs are typically used to reduce the size of tumors, reduce the spread of cancer cells, and reduce the risk of recurrence. Commonly used drugs include hormone therapy, chemotherapy, targeted therapy, and immunotherapy. Hormone therapy is used to reduce the amount of estrogen in the body, while chemotherapy is used to kill cancer cells. Targeted therapy is used to target specific cancer cells, while immunotherapy is used to boost the body's immune system to fight cancer.
Some companies in the Endometrial Cancer Drug market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, and Pfizer. Show Less Read more
